Essential list of medicinal products for rare diseases: recommendations from the IRDiRC Rare Disease Treatment Access Working Group

BACKGROUND: Treatments are often unavailable for rare disease patients, especially in low-and-middle-income countries. Reasons for this include lack of financial support for therapies and onerous regulatory requirements for approval of drugs. Other barriers include lack of reimbursement, administrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gahl, William A., Wong-Rieger, Durhane, Hivert, Virginie, Yang, Rachel, Zanello, Galliano, Groft, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278724/
https://www.ncbi.nlm.nih.gov/pubmed/34256816
http://dx.doi.org/10.1186/s13023-021-01923-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278724/
https://www.ncbi.nlm.nih.gov/pubmed/34256816
http://dx.doi.org/10.1186/s13023-021-01923-0

Ejemplares similares